Date: 2017-08-03
Type of information: Research agreement
Compound:
Company: Cardurion Pharmaceuticals (USA - MA) Takeda Pharmaceutical (Japan)
Therapeutic area: Cardiovascular diseases
Type agreement: research
Action mechanism:
Disease: cardiovascular diseases
Details:
- • On August 3, 2017, Takeda Pharmaceutical and Cardurion Pharmaceuticals announced the creation of a new cardiovascular
development partnership. Cardurion, a recently launched Boston-area based biotechnology company, is focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Cardurion is led by two physician scientists with extensive experience in cardiovascular science, medicine and drug development -- Daniel Bloomfield, M.D., chief executive officer, and Michael Mendelsohn, M.D.,
founder and executive chairman.
- Takeda will jumpstart the new company’s discovery efforts by providing a 12-person cardiovascular research team from its Shonan, Japan site, including fully equipped laboratory space, development resources and licenses to a portfolio of preclinical-stage cardiovascular drug programs.
The newly formed Cardurion is headquartered in Cambridge, Massachusetts and has research facilities in Shonan, Japan -- with both locations surrounded by leading academic research ecosystems that support biotechnology and pharmaceutical companies.
Financial terms:
Latest news:
Is general: Yes
